China accepts Hutchmed fanregratinib NDA on single phase II trial
China accepts Hutchmed fanregratinib NDA on single phase II trial
China accepts Hutchmed fanregratinib NDA on single phase II trial
A rolling strip of the companies, platforms, CROs and device makers that show up across the coverage.
Open about page